Ovid Therapeutics
OVID
57 hedge funds and large institutions have $47.3M invested in Ovid Therapeutics in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 15 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 62 → 57 (-5)
8.14% less ownership
Funds ownership: 37.15% → 29% (-8.1%)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
36% less capital invested
Capital invested by funds: $73.7M → $47.3M (-$26.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$1.86M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$709K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$687K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$638K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$534K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$1.67M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.45M |
| 3 |
AC
AWH Capital
Dallas,
Texas
|
-$1.27M |
| 4 |
SCM
Sio Capital Management
New York
|
-$1.1M |
| 5 |
CCM
Consonance Capital Management
New York
|
-$1.04M |
OVID Hedge Fund Activity: Q1 2020 in Review
57 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2020, worth a combined $47.3M — down 36% from $73.7M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of OVID and 12 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 16 added.
The largest buyer was BVF Inc, adding an estimated $1.86M. The largest seller was Citigroup, cutting an estimated $1.67M.
- 57 institutional investors held Ovid Therapeutics (OVID) as of Q1 2020, down from 62 in Q4 2019.
- Funds reported $47.3M of Ovid Therapeutics stock for Q1 2020, down 36% quarter-over-quarter.
- 12 funds opened new Ovid Therapeutics positions in Q1 2020 and 15 closed out, a net change of -3 holders.
- The largest Ovid Therapeutics buyer in Q1 2020 was BVF Inc, an estimated $1.86M added.
- The largest Ovid Therapeutics seller in Q1 2020 was Citigroup, an estimated $1.67M sold.
Based on aggregated 13F filings for Q1 2020.